dexmedetomidine hydrochloride

FDA Drug Profile — DEXMEDETOMIDINE HYDROCHLORIDE, Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride, Dexmedetomidine Hydrochloride

dexmedetomidine hydrochloride is listed in the FDA National Drug Code directory with 15 NDC codes, marketed under brand names including DEXMEDETOMIDINE HYDROCHLORIDE, Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride, Dexmedetomidine Hydrochloride. Available dosage forms: powder, injection, injection, solution, injection, solution, concentrate.

Drug details

Generic Name
dexmedetomidine hydrochloride
Brand Names
DEXMEDETOMIDINE HYDROCHLORIDE, Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride, Dexmedetomidine Hydrochloride
Application Number
ANDA212791
Sponsor
Strem Chemicals, Inc.
NDC Codes
15
Dosage Forms
POWDER, INJECTION, INJECTION, SOLUTION, INJECTION, SOLUTION, CONCENTRATE
Routes
INTRAVENOUS
Active Ingredients
DEXMEDETOMIDINE HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is a alpha 2 -adrenergic receptor agonist indicated for: Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer dexmedetomidine hydrochloride in 0.9% sodium chloride injection by continuous infusion not to exceed 24 hours. ( 1.1 ) Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. ( 1.2 ) Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. ( 1.2 ) 1.1 Intensive Care Unit Sedation Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine hydrochloride in 0.9% sodium chloride injection prior to extubation. 1.2 Procedural Sedation Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. 1.1 Intensive Care Unit Sedation Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection should be administered by continuous infusion not to exceed 24 hours. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection has been continuously infused in mechanically ventilated adult patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue dexmedetomidine hydrochloride in 0.9% sodium chloride injection prior to extubation. 1.2 Procedural Sedation Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures. Dexmedetomidine hydrochloride in 0.9% sodium chloride injection is indicated for sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.